Name

Noxon

Legal name

Noxon GmbH

Website

https://noxon.io

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Neuro-rehabilitation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

Keywords

• Muscle-computer interface
• Neuromuscular electrical stimulation
• Wearable neuro-rehabilitation devices
• Myoelectric signal processing
• Non-invasive medical wearables

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Sale of wearable muscle-computer interface devices (OCIAN) for clinical and therapeutic use in healthcare settings and potentially direct-to-consumer for everyday health management.
2. Therapy Modules: First therapy modules targeting applications such as reducing Parkinson's tremor and restoring motor function after paralysis. Likely subscription or recurring revenue model for therapy delivery and software updates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Noxon develops and manufactures OCIAN, a non-invasive, wearable muscle-computer interface (mCI) platform that combines continuous muscle diagnostics with neuromuscular electrical stimulation in a closed-loop feedback system. The platform translates brain-to-muscle signals into code, tracks and manages muscle health, and delivers real-time personalized therapy for neuro-rehabilitation applications including Parkinson's tremor reduction, spinal cord injury motor function restoration, and multiple sclerosis foot-drop treatment.

Product overview

Noxon offers OCIAN, a unified muscle-computer interface platform that combines wearable hardware with cloud-based analytics. The system comprises three integrated components: DIVR (the compact wearable electronic unit worn on the skin), OCIAN (the core interface technology that decodes muscle signals and delivers neuromuscular stimulation), and OCIAN Hub (the cloud system that processes bidirectional data for closed-loop personalized therapy). The platform targets neuro-rehabilitation applications including tremor reduction for Parkinson's patients and motor function restoration for paralysis, with therapy modules designed for everyday use.

Differentiator

Problem solved

Functional benefit

Brands

• OCIAN: The core muscle-computer interface technology platform that combines continuous muscle diagnostics with neuromuscular electrical stimulation in a wearable device. OCIAN translates brain-to-muscle signals into code, digitally tracks and manages muscle health and neuromuscular activation. It runs on a compact wearable electronic unit called DIVR that captures and transfers bidirectional signals between muscles and the OCIAN Hub cloud system.

Products and services

• OCIAN Muscle-Computer Interface Platform A non-invasive, wearable muscle-computer interface that translates brain-to-muscle signals into code, digitally tracks and manages muscle health, and delivers neuromuscular electrical stimulation in a closed-loop feedback system. Designed for neuro-rehabilitation applications including tremor reduction in Parkinson's patients and motor function restoration after paralysis. Worn on the skin with no surgery required.
• OCIAN Hub Cloud System Cloud-based data processing and therapy delivery platform that captures and processes bidirectional signals between muscles and the cloud, enabling closed-loop control for personalized therapy and continuous muscle health management. Targets healthcare technology partners and clinical users.
• DIVR Wearable Electronic Unit A compact wearable electronic unit that captures and transfers bidirectional signals between muscles and the OCIAN Hub cloud system, functioning as the on-body connector for the OCIAN muscle-computer interface platform. Worn on the skin without surgery.

Quantifiable outcome

• Target market of over 1.1 billion people with muscle-related or neuromuscular diseases globally
• +3 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered core, major and minor.

• University Hospital WürzburgcoreStrategic or Co-development PartnerMedical partner conducting pilot applications for the muscle-computer interface technology, collaborating on applications including tremor reduction for Parkinson's patients and other neurological disorder treatments.
• N-Squared LabcoreStrategic or Co-development PartnerMedical partner collaborating with Noxon on product validation and development of muscle-computer interface applications.
• Collaborative Research Center ReTunemajorStrategic or Co-development PartnerJoint project focused on developing solutions for neurological disorders and movement impairments by correcting disrupted signals between the brain and muscles using the OCIAN platform.
• Spinal Cord Center RummelsbergmajorStrategic or Co-development PartnerPartner in the NeurOne project developing a wearable neuro-bandage to enable people with spinal cord injuries to regain hand function through ultra-thin textile electrodes and AI-powered signal translation.
• FAU (Friedrich-Alexander-Universität Erlangen-Nürnberg)majorStrategic or Co-development PartnerResearch partner in the NeurOne project for spinal cord injury rehabilitation, collaborating on the development of the wearable neuro-bandage system for hand function restoration.
• Munich Institute for Machine Intelligence and RoboticsmajorStrategic or Co-development PartnerResearch partner using OCIAN technology to treat foot drop in multiple sclerosis patients, enabling a smoother walking pattern through muscle-computer interface therapy.
• Grasp AgainminorStrategic or Co-development PartnerPartner in the NeurOne project contributing to the development of the wearable neuro-bandage for people with spinal cord injuries.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Ottobock: Ottobock is a global orthotics and prosthetics incumbent with an FES/neurostimulation portfolio (e.g., Stimulette, MyGait). Comparable on end market (neuro-rehabilitation) and customer base, but operates as a broad medtech conglomerate rather than a focused mCI platform.

Direct peers

• Saol International: Saol markets the SaolStim and other FES devices targeting upper and lower limb paralysis and tremor. Closely comparable product category (neuromuscular electrical stimulation for movement disorders) and clinical buyer profile.
• Neurometrix: Neurometrix (Quell, SENSUS) makes wearable neurostimulation devices for chronic pain and neurological conditions with a subscription/therapy-module model. Closely comparable on the wearable-electrotherapy business model, subscription therapy modules, and DTC/clinic hybrid channel approach.
• Compex (Enovis / DJO): Compex (part of Enovis, formerly DJO Global) sells NMES devices for muscle activation, rehabilitation and sports performance. Direct overlap on the muscle-stimulation hardware category, with Compex extending into the sports/performance segment Noxon also targets.
• Cionic: Cionic makes the Neural Sleeve, a non-invasive wearable that combines surface EMG sensing with functional electrical stimulation to assist movement in people with foot drop, MS, Parkinson's and stroke. Closest direct comparable to Noxon's OCIAN — same non-invasive mCI architecture, same target indications, same B2B clinical go-to-market.
• Bioness (Bioventus): Bioness (acquired by Bioventus) commercializes the L300 Go and similar FES systems for foot drop and upper-limb paralysis from MS, stroke and SCI. Established, FDA-cleared competitor in exactly the neuromuscular electrical stimulation segment Noxon targets.

Regional players

• Rehab-Robotics: Rehab-Robotics (Hong Kong) commercializes robotic rehabilitation devices such as the Hand of Hope for stroke and SCI patients. Comparable end customers (rehab clinics) and overlapping indications, but Asia-centric go-to-market and different modality (robotics vs NMES).

Emerging players

• MindMaze: MindMaze builds digital neuro-rehabilitation platforms combining gamified therapy, brain-computer interface and motion tracking for stroke and SCI recovery. Overlaps with Noxon on neurological rehab use cases but emphasizes software/BCI rather than muscle-stimulation hardware.
• Axinesis: Axinesis develops robotic and sensor-based rehabilitation devices for children and adults with neurological disorders. Adjacent in the neuro-rehab value chain and overlapping customer base (specialized clinics), but focuses on robotic assistance rather than closed-loop muscle stimulation.
• Fourier Intelligence: Fourier Intelligence manufactures rehabilitation robotics and EMG-driven therapy platforms (e.g., RehabHub, ExoMotus) for stroke and SCI patients. Comparable on EMG-driven neuro-rehab, with a broader robotics portfolio and primarily Asia-based distribution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Noxon